Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Clay Gustafson

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Neoplasia (New York, N.Y.)|June 9, 2021
The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53Joanna S Yi, Oscar Sias-Garcia, Nicole Nasholm, et al.
Cancer Discovery|February 1, 2015
The genetics of splicing in neuroblastomaJustin Chen, Christopher S Hackett, Shile Zhang, et al.
Cell Reports|March 7, 2024
ALK upregulates POSTN and WNT signaling to drive neuroblastomaMiller Huang, Wanqi Fang, Alvin Farrel, et al.
The Journal of Experimental Medicine|July 14, 2025
Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastomaMarie Ménard, Hiroyuki Yoda, Nicole Nasholm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2025
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 TrialAlison M Schram, Abdul Rafeh Naqash, Eric B Haura, et al.
Cell Reports|December 2, 2014
Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastomaChristopher S Hackett, David A Quigley, Robyn A Wong, et al.
Cancer Research|January 29, 2021
Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood CancersAdam J Wolpaw, Richard Bayliss, Gabriele Büchel, et al.
Cancer Research|September 11, 2019
Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding InterfaceJessica Koach, Jessica K Holien, Hassina Massudi, et al.
Cancer Cell|September 3, 2019
Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and RelapseLiguo Zhang, Xuelian He, Xuezhao Liu, et al.
The Journal of Clinical Investigation|December 5, 2017
CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2Liying Chen, Gabriela Alexe, Neekesh V Dharia, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Neoplasia (New York, N.Y.)|June 9, 2021
The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53Joanna S Yi, Oscar Sias-Garcia, Nicole Nasholm, et al.
Cancer Discovery|February 1, 2015
The genetics of splicing in neuroblastomaJustin Chen, Christopher S Hackett, Shile Zhang, et al.
Cell Reports|March 7, 2024
ALK upregulates POSTN and WNT signaling to drive neuroblastomaMiller Huang, Wanqi Fang, Alvin Farrel, et al.
The Journal of Experimental Medicine|July 14, 2025
Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastomaMarie Ménard, Hiroyuki Yoda, Nicole Nasholm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2025
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 TrialAlison M Schram, Abdul Rafeh Naqash, Eric B Haura, et al.
Cell Reports|December 2, 2014
Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastomaChristopher S Hackett, David A Quigley, Robyn A Wong, et al.
Cancer Research|January 29, 2021
Drugging the "Undruggable" MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood CancersAdam J Wolpaw, Richard Bayliss, Gabriele Büchel, et al.
Cancer Research|September 11, 2019
Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding InterfaceJessica Koach, Jessica K Holien, Hassina Massudi, et al.
Cancer Cell|September 3, 2019
Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and RelapseLiguo Zhang, Xuelian He, Xuezhao Liu, et al.
The Journal of Clinical Investigation|December 5, 2017
CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2Liying Chen, Gabriela Alexe, Neekesh V Dharia, et al.
Pageof 4